The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | The current BSH guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
Mary Frances McMullin, MD, Queen’s University, Belfast, UK, briefly outlines the current BSH guidelines for the diagnosis and evaluation of prognosis of patients with myelofibrosis (MF). At diagnosis, a full investigation should be performed, including assessing the degree of bone marrow fibrosis, measuring erythropoietin (EPO) level, and undergoing a molecular evaluation and next-generation sequencing (NGS) screening. When evaluating prognosis, an up-to-date scoring system should be used. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Novartis, BMS, GSK; Speaker Bureau: Novartis, GSK, Incyte; Clinical Trial Support: BMS.
